Use of aerosolized levofloxacin for treating cystic fibrosis
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-009/08
A61K-033/06
A61K-033/14
A61K-045/06
A61K-031/5383
출원번호
US-0623168
(2017-06-14)
등록번호
US-10231975
(2019-03-19)
발명자
/ 주소
Loutit, Jeffery S.
Morgan, Elizabeth E.
Dudley, Michael N.
Griffith, David C.
Lomovskaya, Olga
출원인 / 주소
Horizon Orphan LLC
대리인 / 주소
Bennett, Dennis A.
인용정보
피인용 횟수 :
0인용 특허 :
168
초록▼
Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infe
Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.
대표청구항▼
1. A method for treating a pulmonary Pseudomonas aeruginosa infection in a human in need thereof, the method comprising administering via inhalation 240 mg of levofloxacin twice daily for 28 days to the human to treat the pulmonary Pseudomonas aeruginosa infection; wherein the levofloxacin is in a s
1. A method for treating a pulmonary Pseudomonas aeruginosa infection in a human in need thereof, the method comprising administering via inhalation 240 mg of levofloxacin twice daily for 28 days to the human to treat the pulmonary Pseudomonas aeruginosa infection; wherein the levofloxacin is in a solution comprising 90 mg/ml to 110 mg/ml of levofloxacin and 175 mM to 225 mM of a magnesium cation. 2. The method of claim 1, wherein the magnesium cation is in the form of magnesium chloride. 3. The method of claim 2, wherein the solution comprises 100 mg/ml of levofloxacin and 200 mM of magnesium chloride. 4. The method of claim 1, wherein the magnesium cation is in the form of magnesium sulfate. 5. The method of claim 1, wherein the solution is administered by a vibrating mesh nebulizer. 6. The method of claim 1, wherein the solution has a pH from 5 to 7, and an osmolality from 300 mOsmol/kg to 500 mOsmol/kg. 7. The method of claim 1, further comprising administering dornase alpha, azithromycin, salbutamol, pancrelipase, sodium chloride, seretide, vitamin A, vitamin D, vitamin E, vitamin K, or a combination of two or more thereof. 8. The method of claim 1, wherein the human is a pediatric patient. 9. The method of claim 1, wherein the human has cystic fibrosis. 10. A method for treating a pulmonary Pseudomonas aeruginosa infection in a human in need thereof, the method comprising administering via inhalation 240 mg of levofloxacin twice daily for 28 days to the human to treat the pulmonary Pseudomonas aeruginosa infection; wherein the levofloxacin is in a solution comprising 90 mg/ml to 125 mg/ml of levofloxacin and 150 mM to 250 mM of a cation, wherein the cation is a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation. 11. The method of claim 10, wherein the cation is the zinc cation. 12. The method of claim 11, wherein the zinc cation is in the form of zinc chloride. 13. The method of claim 10, wherein the cation is the copper cation. 14. The method of claim 13, wherein the copper cation is in the form of copper chloride. 15. The method of claim 10, wherein the cation is the magnesium cation. 16. The method of claim 15, wherein the magnesium cation is in the form of magnesium chloride. 17. The method of claim 15, wherein the magnesium cation is in the form of magnesium sulfate. 18. The method of claim 10, wherein the solution has a pH from 5 to 7, and an osmolality from 300 mOsmol/kg to 500 mOsmol/kg. 19. The method of claim 10, wherein the human is a pediatric patient. 20. The method of claim 19, wherein the pediatric patient has cystic fibrosis.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
James N. Schmidt CA; Jerry Grychowski ; Daniel K. Engelbreth CA; Robert Morton CA; Martin P. Foley CA, Aerosol medication delivery apparatus and system.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Hodson Peter D. (Trowell GB3) Baum Eric A. (Loughborough GB3) Smith David K. (Loughborough GB3) Kuepper Anton (Kaarst DEX) Wilby Matthew J. (Loughborough GB3), Breath actuated inhaler having an electromechanical priming mechanism.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Mulhauser Paul (New York NY) Karg Jeffrey (Waldwick NY) Foxen Thomas (Brooklyn NY) Brooks Christopher J. (Glen Head NY), Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same.
Domagala John M. (Canton MI) Kiely John S. (Ann Arbor MI) Schroeder Mel C. (Dexter MI), Individual stereosiomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents.
Burns James S. (Darien CT) Marshak Daniel R. (Cold Spring Harbor NY), Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Hess Joseph,CHX ; Bo Hu,CHX ; Weber Raphael,CHX ; Ortega Isabel,CHX ; Barraud Cedric,CHX ; van der Schoot Bart,CHX ; de Rooij Nicolaas Frans,CHX ; de Heij Bas,CHX, Liquid droplet spray device for an inhaler suitable for respiratory therapies.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Blineau Joseph (Rennes FRX) Pommier Daniel (Mordelles FRX) Thomas Claude (Chasne sur Illet FRX), Multiplex channels for continuous flow for numerical signal.
Nowacki Christopher (Arlington Heights IL) Brisson Alfred G. (Kildeer IL) Dela-Cruz Exequiel (Arlington Heights IL), Pediatric asthmatic medication inhaler.
Arnold Klaus (Ingelheim am Rhein DEX) Grass Peter (Ingelheim am Rhein DEX) Knecht Adolf (Freiburg DEX) Roos Robert (Ingelheim am Rhein DEX) Sluke Gerhard (Ingelheim am Rhein DEX) Thieme Herbet (Ingel, Powders for inhalation.
Knight Jack V. (Houston TX) Wilson ; Jr. Samuel Z. (Houston TX), Small particle aerosol generator for treatment of respiratory disease including the lungs.
Barbachyn Michael R. (Kalamazoo MI) Brickner Steven J. (Portage MI) Hutchinson Douglas K. (Kalamazoo MI), Substituted oxazine and thiazine oxazolidinone antimicrobials.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
Welsh, Michael J.; Zabner, Joseph, Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.